Exponent (NASDAQ:EXPO) Issues Quarterly Earnings Results

Exponent (NASDAQ:EXPO) posted its quarterly earnings data on Thursday. The business services provider reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04, FiscalAI reports. Exponent had a return on equity of 31.48% and a net margin of 17.67%. The firm had revenue of $173.73 million for the quarter, compared to analysts’ expectations of $149.64 million. During the same quarter last year, the business earned $0.55 EPS. The company’s quarterly revenue was up 11.7% compared to the same quarter last year.

Here are the key takeaways from Exponent’s conference call:

• Strong third-quarter performance: Net revenue rose 12% to $153.1 million, EBITDA increased 16% with margin expanding to 29.4%, and utilization reached 76.7%. The company cited broad-based demand across user research, disputes, failure analysis, and product safety.
• Exponent raised its full-year 2026 outlook to 10%-11% net revenue growth and 28%-28.3% EBITDA margin, up from 27.6% in 2025. Management expects strong business activity to continue despite seasonally lower fourth-quarter utilization.
• AI-related work now represents an estimated 15%-20% of the business, spanning data-center infrastructure, advanced transportation systems, user research, product safety, and explainability of AI-driven decisions. Management said inquiries are increasing as AI moves into physical products and real-world applications.
• The engineering and scientific segment grew 13%, while environmental and health revenue increased only 3%. Management is investing in senior talent and emerging-chemical capabilities, including PFAS-related work, to support a future reacceleration.
• Exponent returned capital through $171 million of stock repurchases over the past 12 months, reducing diluted shares outstanding by 5%, and paid $14.7 million in dividends during the quarter. No shares were repurchased in the third quarter, but $50 million remains authorized for future buybacks.

Exponent Trading Up 1.6%

EXPO stock traded up $1.20 during mid-day trading on Thursday, hitting $78.31. The stock had a trading volume of 879,325 shares, compared to its average volume of 573,694. Exponent has a 52 week low of $51.91 and a 52 week high of $81.95. The firm has a market capitalization of $3.72 billion, a P/E ratio of 34.58 and a beta of 0.69. The firm has a fifty day simple moving average of $69.81 and a 200 day simple moving average of $66.59.

Key Exponent News

Here are the key news stories impacting Exponent this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. Exponent reported diluted EPS of $0.64, up from $0.55 a year earlier and above the $0.60 consensus estimate. Revenue rose 11.7% year over year to $173.73 million, substantially ahead of analysts’ $149.64 million forecast. Exponent Tops Q3 Earnings and Revenue Estimates
• Positive Sentiment: Profitability and cash generation remained healthy. Operating profit reportedly increased 44.2% year over year to $41.9 million, while operating cash flow reached $30.9 million. Exponent ended the quarter with $114.7 million in cash and limited capital spending, supporting financial flexibility. Exponent Q3 2026 Earnings Results
• Positive Sentiment: Management raised its 2026 outlook. The improved forecast reinforces expectations that demand for Exponent’s engineering and scientific consulting services will remain solid. Exponent Raises 2026 Outlook
• Positive Sentiment: Exponent declared a $0.31 quarterly dividend, payable December 18 to shareholders of record December 4, providing an additional shareholder-return signal. Exponent Declares Quarterly Dividend
• Neutral Sentiment: Exponent also announced plans to acquire Crane Building Services & Utilities in a carve-out transaction. The deal could expand its services platform, but financial terms and the expected earnings impact were not provided. Exponent to Acquire Crane Building Services and Utilities
• Negative Sentiment: Recent insider activity was heavily weighted toward selling, with 10 sales versus one purchase over the past six months. While insider sales do not necessarily indicate deteriorating fundamentals, they may temper investor enthusiasm.

Insider Buying and Selling at Exponent

In related news, CEO Catherine Corrigan sold 1,707 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $66.28, for a total transaction of $113,139.96. Following the sale, the chief executive officer owned 129,108 shares in the company, valued at approximately $8,557,278.24. This trade represents a 1.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on EXPO. JPMorgan Chase & Co. boosted their price objective on shares of Exponent from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 31st. UBS Group set a $72.00 target price on shares of Exponent and gave the stock a “neutral” rating in a report on Friday, July 31st. Finally, Weiss Ratings upgraded shares of Exponent from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 9th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.00.

Exponent Company Profile

Exponent, Inc is a science and engineering consulting company that helps clients investigate complex technical issues, manage risks, and develop solutions. Its consultants work across disciplines including engineering, materials science, biomechanics, human factors, environmental science, health, data sciences, and economics.

The company provides failure analysis, product safety and testing, accident reconstruction, environmental and health assessments, regulatory support, and expert testimony.